Abstract

Nowadays, nobody compared the intrinsic diagnostic power of FDG PET TC with Amy-PET when we have a patient affected by a minor form of mild cognitive impairment (MCI), in a prodromal stage of neuro cognitive impairment, when neuropsychological examination excludes not only impairment in activities of daily living (ADL) but also in instrumental activities of daily living (IADL). In this stage, more often, cerebral FDG PET TAC still demonstrates a normal metabolism of glucose in the cortical areas of the brain. We aimed to detect the role of cerebral Amy PET TC in determining the possible evolution from Neurocognitive and Mild Cognitive impairment, when cerebral FDG PET TAC doesn’t still notice an alteration in glucose metabolism in the brain. This preliminary study let us to consider cerebral Amy PET TC very useful in a prodromic phase, named neurocognitive impairment, when the patient demonstrates, at neuropsychological test, a situation similar to “aging brain”.